<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05070819</url>
  </required_header>
  <id_info>
    <org_study_id>0394227092021</org_study_id>
    <nct_id>NCT05070819</nct_id>
  </id_info>
  <brief_title>Atrial Natriuretic Peptide in Assessing Fluid Status</brief_title>
  <official_title>Role of Atrial Natriuretic Peptide in Assessing of Fluid Status in Cardiac Surgery Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Petrovsky National Research Centre of Surgery</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Petrovsky National Research Centre of Surgery</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Biomarkers can play a significant role in fluid status assessment intraoperatively.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Routinely intraoperatively the fluid status assessment is based on central venous pressure&#xD;
      and other pressometric parameters. Nevertheless, the minority of anesthesiologists use&#xD;
      continious dynamic parameters like pulse pressure variation, stroke volume variation and&#xD;
      other to manage fluid status. There's a fast acting biomarker that can help anesthesiologist&#xD;
      to diagnose and manage the volemic status and possibly guide the infusion therapy better.&#xD;
&#xD;
      Pro-ANP is a biomarker that reacts on atria strain and can be used in volemic status&#xD;
      assessment in cardiac surgery patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hypervolemia episodes</measure>
    <time_frame>intraoperatively</time_frame>
    <description>Based on hemodynamic, clinical and laboratory monitoring consistent intraoperative assessment of hypervolemia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hypovolemia episodes</measure>
    <time_frame>intraoperatively</time_frame>
    <description>Based on hemodynamic, clinical and laboratory monitoring consistent intraoperative assessment of hypovolemia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>up to 10 days</time_frame>
    <description>Total amount of various postoperative complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>up to 10 days</time_frame>
    <description>Mortality rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiorgan failure</measure>
    <time_frame>up to 10 days</time_frame>
    <description>Number of more than 2 organs failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory failure</measure>
    <time_frame>up to 10 days</time_frame>
    <description>Number of patients who require prolonged and/or repeated artificial lung ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal failure</measure>
    <time_frame>up to 10 days</time_frame>
    <description>Number of patients who require extracorporeal detoxication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart failure</measure>
    <time_frame>up to 10 days</time_frame>
    <description>Need in medicamental cardiotonic support more than 1 day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulatory insufficiency</measure>
    <time_frame>up to 10 days</time_frame>
    <description>Need in medicamental vasopressor support more than 1 day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection rate</measure>
    <time_frame>up to 10 days</time_frame>
    <description>Number of patients who develop systemic infection and/or operation wound infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of intensive care stay</measure>
    <time_frame>up to 10 days</time_frame>
    <description>Duration of summarized length in ICU, including readmission to ICU</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Fluid Overload</condition>
  <condition>Fluid Loss</condition>
  <condition>Volume Overload</condition>
  <condition>Cardiac Disease</condition>
  <condition>Cardiac Output, Low</condition>
  <condition>Cardiac Output, High</condition>
  <arm_group>
    <arm_group_label>Cardiac surgery patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After admission to OR and arterial catheter is placed the pro-ANP probe is obtained.&#xD;
After anesthesia induction, trachea intubation before Teboul' test pro-ANP is obtained&#xD;
At the end of Teboul' test when lower limbs are lifted&#xD;
30 minutes of CPB&#xD;
End of CPB&#xD;
End of volume transtion from CPB circuit to patient&#xD;
Before Teboul' test at the end of surgery&#xD;
End of Teboul' test when lower limbs are lifted</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>pro-ANP</intervention_name>
    <description>pro-ANP samples and fluid status assessment with functional tests (Teboul test) will be used 8 times intraoperatively.</description>
    <arm_group_label>Cardiac surgery patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        CABG, one-, two valve repair/replacement, ascending aorta, aortic arch replacement, ASD/AVD&#xD;
        closurer, septal myoectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Atrial fibrillation, atrial flutter, frequent ventricular and supraventricular&#xD;
             arrythmias&#xD;
&#xD;
          2. EFLV &lt; 50%&#xD;
&#xD;
          3. Pulmonary hypertension &gt; 2 st&#xD;
&#xD;
          4. CKD &gt; C3 (GFR &lt; 30)&#xD;
&#xD;
          5. Redo surgery&#xD;
&#xD;
          6. Left atrium volume &gt; 150 ml&#xD;
&#xD;
          7. LV EDV &gt; 250 ml&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boris Akselrod, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Petrovsky RNCS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Artem Gubko, Ph.D.</last_name>
    <phone>+79684241490</phone>
    <email>gubko@artvig.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Petrovsky Research National Centre of Surgery (Petrovsky NRCS)</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Artem Gubko, Ph.D.</last_name>
      <phone>+79684241490</phone>
      <email>gubko@artvig.ru</email>
    </contact>
    <investigator>
      <last_name>Denis Guskov, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Boris Akselrod, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 7, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fluid responsiveness</keyword>
  <keyword>fluid status</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>volemic status</keyword>
  <keyword>pro-ANP</keyword>
  <keyword>hemodynamic monitoring</keyword>
  <keyword>functional test</keyword>
  <keyword>teboul test</keyword>
  <keyword>stroke volume variation</keyword>
  <keyword>cardiac output</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Cardiac Output, Low</mesh_term>
    <mesh_term>Cardiac Output, High</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

